Pasithea Therapeutics posts press release on PAS-004 data presentation at ESMO 2026
KTTA•PAS-004 presentation at ESMO 2026
- Pasithea posted a new press release on PAS-004 ahead of an ESMO Congress 2026 poster on its Phase 1 dose-escalation study.
- The poster is scheduled for Oct. 23, 2026 in Madrid, covering safety and pharmacokinetics in MAPK pathway-driven advanced solid tumors.
- The abstract will publish on the ESMO website under the congress embargo schedule.
- Release: https://d1io3yog0oux5.cloudfront.net/_778f3af0f0856ee1c68f689721c93ae2/pasithea/news/2026-07-21_Pasithea_Therapeutics_Announces_Presentation_of_146.pdf
